THE D-1 DOPAMINE RECEPTOR PARTIAL AGONIST, CY 208-243, EXHIBITS ANTIPARKINSONIAN ACTIVITY IN THE MPTP-TREATED MARMOSET

被引：59
|
作者：
TEMLETT, JA
PIANG, NC
OERTEL, WH
JENNER, P
MARSDEN, CD
机构：
[1] UNIV LONDON,DEPT NEUROL,MRC,MOVEMENT DISORDERS RES GRP,LONDON SE5 8AF,ENGLAND
[2] INST PSYCHIAT,PARKINSONS DIS SOC RES CTR,LONDON SE5,ENGLAND
[3] UNIV LONDON KINGS COLL HOSP,SCH MED,LONDON SE5 8RX,ENGLAND
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 1988年 / 156卷 / 02期
关键词：
D O I：
10.1016/0014-2999(88)90322-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [41] Dopamine D1B receptor chimeras reveal modulation of partial agonist activity by carboxyl-terminal tail sequences
    Sugamori, KS
    Scheideler, MA
    Vernier, P
    Niznik, HB
    JOURNAL OF NEUROCHEMISTRY, 1998, 71 (06) : 2593 - 2599
  • [42] DOPAMINE AGONIST-INDUCED LOCOMOTOR-ACTIVITY IN RATS TREATED WITH 6-HYDROXYDOPAMINE AT DIFFERING AGES - FUNCTIONAL SUPERSENSITIVITY OF D-1 DOPAMINE-RECEPTORS IN NEONATALLY LESIONED RATS
    BREESE, GR
    NAPIER, TC
    MUELLER, RA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1985, 234 (02): : 447 - 455
  • [43] Kinetics of the uptake and distribution of the dopamine D2,3 agonist (R)-N-[1-11C]n-propylnorapomorphine in brain of healthy and MPTP-treated Gottingen miniature pigs
    Cumming, P
    Gillings, NM
    Jensen, SB
    Bjarkam, C
    Gjedde, A
    NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (05) : 547 - 553
  • [44] The cannabinoid receptor agonist WIN 55,212-2 reduces D-2, but not D-1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease
    Maneuf, YP
    Crossman, AR
    Brotchie, JM
    EXPERIMENTAL NEUROLOGY, 1997, 148 (01) : 265 - 270
  • [45] β-Lactotensin derived from bovine β-lactoglobulin exhibits anxiolytic-like activity as an agonist for neurotensin NTS2 receptor via activation of dopamine D1 receptor in mice
    Hou, I-Ching
    Suzuki, Chihiro
    Kanegawa, Norimasa
    Oda, Ayako
    Yamada, Ayako
    Yoshikawa, Masaaki
    Yamada, Daisuke
    Sekiguchi, Masayuki
    Wada, Etsuko
    Wada, Keiji
    Ohinata, Kousaku
    JOURNAL OF NEUROCHEMISTRY, 2011, 119 (04) : 785 - 790
  • [46] Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity
    Betry, C.
    Etievant, A.
    Lambas-Senas, L.
    McCreary, A.
    Haddjeri, N.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S117 - S117
  • [47] Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists
    Simola, Nicola
    Fenu, Sandro
    Baraldi, Pier G.
    Tabrizi, Mojgan Aghazadeh
    Morelli, Micaela
    SYNAPSE, 2008, 62 (05) : 345 - 351
  • [48] In Vivo Effects of Pardoprunox (SLV308), a Partial D2/D3 Receptor and 5-HT1A Receptor Agonist, on Rat Dopamine and Serotonin Neuronal Activity
    Betry, Cecile
    Etievant, Adeline
    Lambas-Senas, Laura
    Mccreary, Andrew C.
    Haddjeri, Nasser
    SYNAPSE, 2011, 65 (10) : 1042 - 1051
  • [49] Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice
    Boeckler, F
    Leng, A
    Mura, A
    Bettinetti, L
    Feldon, J
    Gmeiner, P
    Ferger, B
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (06) : 1025 - 1032
  • [50] F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
    Marie-Bernadette Assié
    Laurent Bardin
    Agnès Auclair
    Nathalie Consul-Denjean
    François Sautel
    Ronan Depoortère
    Adrian Newman-Tancredi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 375 : 241 - 250
12345